Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-01-14
2002-06-04
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S336000, C544S387000, C514S183000
Reexamination Certificate
active
06399613
ABSTRACT:
The present invention relates to medicaments containing, as active principle, a compound of formula:
a stereoisomer or a salt of such a compound with an inorganic or organic acid, to the novel compounds of formula (I) and to a process for their preparation.
In formula (I) either
R represents a nitrogen atom, R
1
represents a radical —CO—NR
5
R
6
, —CO—N(CH(CH
2
OH)
2
)
2
, —CO—N(CH
2
OH)
2
, —CO—N(CH
2
—CH(CH
2
OH)
2
)
2
, —CO—N(CH
2
—(CHOH)
n
—CH
2
OH)
2
in which n is equal to 0, 1, 2, 3 or 4, —CH
2
—O—R
6
, —NR
5
—CO—R
6
, —CH
2
—NR
5
R
6
, —CH
2
—N (CH
2
OH)
2
, —CH
2
—N(CH
2
—(CHOH)
y
—CH
2
OH)
2
in which y is equal to 0, 1, 2, 3 or 4, —CH
2
—N(CH(CH
2
OH)
2
)
2
or —CH
2
—N(CH
2
—CH(CH
2
OH)
2
)
2
and one of the substituents R
3
or R
4
represents a hydrogen atom and the other is identical to R
1
and R
2
represents a hydrogen atom, or R represents a CH residue, R
1
and R
4
are identical and each represent a radical —CO—NR
5
R
6
, —CO—N(CH(CH
2
OH)
2
)
2
, —CO—N(CH
2
OH)
2
, —CO—N(CH
2
—CH(CH
2
OH)
2
)
2
, —CO—N(CH
2
—(CHOH)
n
—CH
2
OH)
2
in which n is equal to 0, 1, 2, 3 or 4, —CH
2
—O—R
6
, —NR
5
—CO—R
6
, —CH
2
—NR
5
R
6
, —CH
2
—N(CH
2
OH)
2
, —CH
2
—N(CH
2
—(CHOH)
y
—CH
2
OH)
2
in which y is equal to 0, 1, 2, 3 or 4, —CH
2
—N(CH(CH
2
OH)
2
)
2
or —CH
2
—N(CH
2
—CH(CH
2
OH)
2
)
2
and R
2
and R
3
each represent a hydrogen atom, or R represents a CH residue, R
1
and R
3
are identical and each represent a radical —CO—NR
5
R
6
, —CO—N(CH(CH
2
OH)
2
)
2
, —CO—N(CH
2
OH)
2
, —CO—N(CH
2
—CH(CH
2
OH)
2
)
2
, —CO—N(CH
2
—(CHOH)
n
—CH
2
OH)
2
in which n is equal to 0, 1, 2, 3 or 4, —CH
2
—O—R
6
, —NR
5
—CO—R
6
, —CH
2
—NR
5
R
6
, —CH
2
—N(CH
2
OH)
2
, —CH
2
—N(CH
2
—(CHOH)
y
—CH
2
OH)
2
in which y is equal to 0, 1, 2, 3 or 4, —CH
2
—N(CH(CH
2
OH)
2
)
2
or —CH
2
—N(CH
2
—CH(CH
2
OH)
2
)
2
and R
2
and R
4
each represent a hydrogen atom,
or R represents a CH residue, R
2
and R
3
are identical and each represent a radical —CO—NR
5
R
6
, —CO—N(CH(CH
2
OH)
2
)
2
, —CO—N(CH
2
OH)
2
, —CO—N(CH
2
—CH(CH
2
OH)
2
)
2
, —CO—N(CH
2
—(CHOH)
n
—CH
2
OH)
2
in which n is equal to 0, 1, 2, 3 or 4, —CH
2
—O—R
6
, —NR
5
—CO—R
6
, —CH
2
—NR
5
R
6
, —CH
2
—N(CH
2
OH)
2
, —CH
2
—N(CH
2
—(CHOH)
y
—CH
2
OH)
2
in which y is equal to 0, 1, 2, 3 or 4, —CH
2
—N(CH(CH
2
OH)
2
)
2
or —CH
2
—N(CH
2
—CH(CH
2
OH)
2
)
2
and R
1
and R
4
each represent a hydrogen atom,
R
5
represents a hydrogen atom or an alkyl radical,
R
6
represents a radical —CH
2
—(CHOH)m—CH
2
OH in which m is equal to 0, 1, 2, 3 or 4, -alk-O-alk-CH
2
OH, -alk-O-alk, —CH(CH
2
OH)
2
, —C(CH
2
OH)
3
, —C(CH
3
) (CH
2
OH)
2
, —CH
2
—CH(CH
2
OH)
2
or —CH(CH
2
OH)—(CHOH)
x
—CH
2
OH in which x is equal to 1, 2, 3 or 4,
alk represents an alkyl radical.
In the definitions hereinabove and in those hereinbelow, the alkyl radicals contain 1 to 6 carbon atoms in a straight or branched chain.
The compounds of formula (I) containing asymmetric carbon atoms have stereoisomeric forms. These stereoisomers form part of the invention.
The preferred medicaments are those which contain a compound of formula (I) chosen from the following compounds:
N,N′-bis(2-hydroxyethyl)pyrazine-2,5-dicarboxamide,
N,N′-bis(2-hydroxyethyl)pyrazine-2,6-dicarboxamide,
N-methyl-N-(2-hydroxyethyl-N′-methyl-N′(2-hydroxyethyl)pyrazine-2,5-dicarboxamide,
N-methyl-N-(2-hydroxyethyl)-N′-methyl-N′(2-hydroxyethyl)pyrazine-2,6-dicarboxamide,
N,N,N′,N′-tetrakis(2-hydroxyethyl)pyrazine-2,5-dicarboxamide,
N,N,N′,N′-tetrakis(2-hydroxyethyl)pyrazine-2,6-dicarboxamide,
N,N′-bis(2,3-dihydroxy-1-propyl)pyrazine-2,5-dicarboxamide,
N,N′-bis(2,3-dihydroxy-1-propyl)pyrazine-2,6-dicarboxamide,
N-methyl-N-(2,3-dihydroxy-1-propyl)-N′-methyl-N′-(2,3-dihydroxy-1-propyl)pyrazine-2,5-dicarboxamide,
N-methyl-N-(2,3-dihydroxy-1-propyl)-N′-methyl-N′-(2,3-dihydroxy-1-propyl)pyrazine-2,6-dicarboxamide,
N,N,N′,N′-tetrakis(2,3-dihydroxy-1-propyl)pyrazine-2,5-dicarboxamide,
N,N,N′,N′-tetrakis(2,3-dihydroxy-1-propyl)pyrazine-2,6-dicarboxamide,
N,N′-bis(1,3-dihydroxy-2-propyl)pyrazine-2,5-dicarboxamide,
N,N′-bis(1,3-dihydroxy-2-propyl)pyrazine-2,6-dicarboxamide,
N-methyl-N-(1,3-dihydroxy-2-propyl)-N′-methyl-N′-(1,3-dihydroxy-2-propyl)pyrazine-2,5-dicarboxamide,
N-methyl-N-(1,3-dihydroxy-2-propyl)-N′-methyl-N′-(1,3-dihydroxy-2-propyl)pyrazine-2,6-dicarboxamide,
N,N,N′,N′-tetrakis(1,3-dihydroxy-2-propyl)pyrazine-2,5-dicarboxamide,
N,N,N′,N′-tetrakis(1,3-dihydroxy-2-propyl)pyrazine-2,6-dicarboxamide,
N,N′-bis(2,3,4-trihydroxy-1-butyl)pyrazine-2,5-dicarboxamide,
N,N′-bis(2,3,4-trihydroxy-1-butyl)pyrazine-2,6-dicarboxamide,
N-methyl-N-(2,3,4-trihydroxy-1-butyl)-N′-methyl-N′-(2,3,4-trihydroxy-1-butyl)pyrazine-2,5-dicarboxamide,
N-methyl-N-(2,3,4-trihydroxy-1-butyl)-N′-methyl-N′-(2,3,4-trihydroxy-1-butyl)pyrazine-2,6-dicarboxamide,
N,N′-bis(1,3,4-trihydroxy-2-butyl)pyrazine-2,5-dicarboxamide,
N,N′-bis(1,3,4-trihydroxy-2-butyl)pyrazine-2,6-dicarboxamide,
N-methyl-N-(1,3,4-trihydroxy-2-butyl)-N′-methyl-N′-(1,3,4-trihydroxy-2-butyl)pyrazine-2,5-dicarboxamide,
N-methyl-N-(1,3,4-trihydroxy-2-butyl)-N′-methyl-N′-(1,3,4-trihydroxy-2-butyl)pyrazine-2,6-dicarboxamide,
N,N′-bis[2-(hydroxymethyl)-3-hydroxy-1-propyl]-pyrazine-2,5-dicarboxamide,
N,N′-bis[2-(hydroxymethyl)-3-hydroxy-1-propyl]-pyrazine-2,6-dicarboxamide,
N-methyl-N-[2-(hydroxymethyl)-3-hydroxy-1-propyl]-N′-methyl-N′-[2-(hydroxymethyl)-3-hydroxy-1-propyl]-pyrazine-2,5-dicarboxamide,
N-methyl-N-[2-(hydroxymethyl)-3-hydroxy-1-propyl]-N′-methyl-N′-[2-(hydroxymethyl)-3-hydroxy-1-propyl]-pyrazine-2,6-dicarboxamide,
N,N,N′,N′-tetrakis[2-(hydroxymethyl)-3-hydroxy-1-propyl]pyrazine-2,5-dicarboxamide,
N,N,N′,N′-tetrakis[2-(hydroxymethyl)-3-hydroxy-1-propyl]pyrazine-2,6-dicarboxamide,
N,N′-bis[1,1,1-tri(hydroxymethyl)methyl]pyrazine-2,5-dicarboxamide,
N,N′-bis[1,1,1-tri(hydroxymethyl)methyl]pyrazine-2,6-dicarboxamide,
N-methyl-N-[1,1,1-tri(hydroxymethyl)methyl]-N′-methyl-N′-[1,1,1-tri(hydroxymethyl)methyl]pyrazine-2,5-dicarboxamide,
N-methyl-N-[1,1,1-tri(hydroxymethyl)methyl]-N′-methyl-N′-[1,1,1-tri(hydroxymethyl)methyl]pyrazine-2,6-dicarboxamide,
N,N′-bis[1,1-di(hydroxymethyl)-1-ethyl]pyrazine-2,5-dicarboxamide,
N,N′-bis[1,1-di(hydroxymethyl)-1-ethyl]pyrazine-2,6-dicarboxamide,
N-methyl-N-[1,1-di(hydroxymethyl)-1-ethyl]-N′-methyl-N′-[1,1-di(hydroxymethyl)-1-ethyl]pyrazine-2,5-dicarboxamide,
N-methyl-N-[1,1-di(hydroxymethyl)-1-ethyl]-N′-methyl-N′-[1,1-di(hydroxymethyl)-1-ethyl]pyrazine-2,6-dicarboxamide,
N,N′-bis(2-hydroxyethyl)pyridine-2,5-dicarboxamide,
N,N′-bis(2-hydroxyethyl)pyridine-2,6-dicarboxamide,
N,N′-bis(2-hydroxyethyl)pyridine-3,5-dicarboxamide,
N-methyl-N-(2-hydroxyethyl)-N′-methyl-N′-(2-hydroxyethyl)pyridine-2,5-dicarboxamide,
N-methyl-N-(2-hydroxyethyl)-N′-methyl-N′-(2-hydroxyethyl)pyridine-2,6-dicarboxamide,
N-methyl-N-(2-hydroxyethyl)-N′-methyl-N′-(2-hydroxyethyl)pyridine-3,5-dicarboxamide,
N,N,N′,N′-tetrakis(2-hydroxyethyl)pyridine-2,5-dicarboxamide,
N,N,N′,N′-tetrakis(2-hydroxyethyl)pyridine-2,6-dicarboxamide,
N,N,N′,N′-tetrakis(2-hydroxyethyl)pyridine-3,5-dicarboxamide,
N,N′-bis(2,3-dihydroxy-1-propyl)pyridine-2,5-dicarboxamide,
N,N′-bis(2,3-dihydroxy-1-propyl)pyridine-2,6-dicarboxamide,
N,N′-bis(2,3-dihydroxy-1-propyl)pyridine-3,5-dicarboxamide,
N-methyl-N-(2,3-dihydroxy-1-propyl)-N′-methyl-N′-(2,3-dihydroxy-1-propyl)pyridine-2,5-dicarboxamide,
N-methyl-N-(2,3-dihydroxy-1-propyl)-N′-methyl-N′-(2,3-dihydroxy-1-propyl)pyridine-2,6-
Bashiardes Georges
Carry Jean-Christophe
Evers Michel
Filoche Bruno
Mignani Serge
Aventis Pharma S.A.
Newman Irving
Patel Sudhaker B.
Raymond Richard L.
LandOfFree
Pyrazine derivatives, their preparation and medicaments... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazine derivatives, their preparation and medicaments..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazine derivatives, their preparation and medicaments... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2894531